Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Private cancer therapeutics developer Gloucester Pharmaceuticals has initiated a pivotal trial of FK228 in cutaneous T-cell lymphoma, following the receipt of trial protocol approval from the FDA.
Subscribe to our email newsletter
The grant entails a collaborative effort between researchers at Micronics and the Seattle Children’s Research Institute (SCRI), in which a novel primer design method that enables detection of distantly related gene sequences will be used with Micronics’ microfluidic molecular diagnostic test platform.
Grant funding for this effort is from the National Institute of Allergy and Infectious Diseases under the National Institutes of Health (NIH), award number 1R43 AI084851-01.
Micronics is engaged in point of care tests for molecular detection of infectious diseases.